Serine protease inhibitor Kazal type 1 (SPINK1) as a prognostic marker in stage IV colon cancer patients receiving cetuximab based targeted therapy.

Autor:	Yi-Ting Chen, Shu-Chuan Tsao, Hung-Pei Tsai, Jaw-Yuan Wang, Chee-Yin Chai
Předmět:	SERINE proteinase inhibitors COLON cancer prognosis CETUXIMAB BIOMARKERS PROTEIN expression THERAPEUTICS
Zdroj:	Journal of Clinical Pathology; Nov2016, Vol. 69 Issue 11, p974-978, 5p, 1 Color Photograph, 2 Charts, 1 Graph
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu